Pacific Biosciences of California, Inc.

How big is Pacific Biosciences of California, Inc.?

As of Jun 18, Pacific Biosciences of California, Inc. has a market capitalization of 390.11 million, with net sales of 152.35 million and a net profit of -656.55 million over the last four quarters. Shareholder's funds are at 506.59 million, and total assets amount to 1,260.45 million.

As of Jun 18, Pacific Biosciences of California, Inc. has a market capitalization of 390.11 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 152.35 million, while the sum of net profit for the same period is -656.55 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds at 506.59 million and total assets amounting to 1,260.45 million.

What does Pacific Biosciences of California, Inc. do?

Pacific Biosciences of California, Inc. designs and manufactures genetic sequencing systems in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of $37 million and a net loss of $426 million, with a market cap of $390.11 million.

Overview: <BR>Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems for genetic analysis, operating within the Pharmaceuticals & Biotechnology industry and categorized as a Micro Cap company.<BR><BR>Financial Snapshot: <BR>Net Sales: 37 Million (Quarterly Results - Mar 2025) <BR>Net Profit: -426 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 390.11 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 3.33 <BR>Return on Equity: -650.30% <BR>Price to Book: 4.26<BR><BR>Contact Details: <BR>Address: 1305 O'brien Drive, MENLO PARK CA: 94025 <BR>Tel: 1 650 5218000 <BR>Fax: 1 302 6365454 <BR>Website: https://www.pacb.com/

Should I buy, sell or hold Pacific Biosciences of California, Inc.?

Who are in the management team of Pacific Biosciences of California, Inc.?

As of March 2022, the management team of Pacific Biosciences of California, Inc. includes Dr. John Milligan (Independent Chairman), Mr. Christian Henry (CEO), and several directors including Dr. Michael Hunkapiller, Ms. Kathy Ordonez, Dr. David Botstein, Mr. William Ericson, and Mr. Randall Livingston. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Pacific Biosciences of California, Inc. includes the following individuals:<BR><BR>- Dr. John Milligan, Independent Chairman of the Board<BR>- Mr. Christian Henry, President, Chief Executive Officer, Director<BR>- Dr. Michael Hunkapiller, Director<BR>- Ms. Kathy Ordonez, Director<BR>- Dr. David Botstein, Independent Director<BR>- Mr. William Ericson, Independent Director<BR>- Mr. Randall Livingston, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Is Pacific Biosciences of California, Inc. overvalued or undervalued?

As of April 29, 2021, Pacific Biosciences of California, Inc. is considered a risky investment due to its overvaluation and poor financial metrics, reflected in a year-to-date return of -30.05% and a five-year decline of -84.26%, significantly underperforming the S&P 500.

As of 29 April 2021, the valuation grade for Pacific Biosciences of California, Inc. moved from fair to risky, indicating a deterioration in its investment appeal. The company appears to be overvalued given its negative financial metrics, with a Price to Book Value of 3.73, an EV to EBIT of -1.06, and an EV to EBITDA of -3.29. Comparatively, its peer, which has a valuation of risky, shows a P/E of -0.6779 and an EV to EBITDA of -4.2891, further highlighting the company's relative weakness.<BR><BR>The company's recent stock performance has been significantly underwhelming, with a year-to-date return of -30.05% compared to the S&P 500's 12.22%, and a staggering decline of -84.26% over the past five years against the S&P 500's 96.61% gain. This stark contrast reinforces the view that Pacific Biosciences is overvalued in its current state.

Is Pacific Biosciences of California, Inc. technically bullish or bearish?

As of August 25, 2025, Pacific Biosciences of California, Inc. is in a mildly bearish trend, indicated by bearish MACD and moving averages, with a year-to-date return of -30.05% compared to the S&P 500's 12.22%.

As of 25 August 2025, the technical trend for Pacific Biosciences of California, Inc. has changed from sideways to mildly bearish. The current technical stance is bearish, with key indicators supporting this view including a bearish MACD on the weekly timeframe and bearish moving averages on the daily timeframe. Additionally, the Dow Theory indicates a mildly bearish stance on both weekly and monthly periods. <BR><BR>In terms of performance, the stock has underperformed significantly compared to the S&P 500, with a year-to-date return of -30.05% versus the S&P 500's 12.22%, and a one-year return of -33.68% compared to the S&P 500's 17.14%.